At Roche and Genentech, we are leveraging our unique company structure and culture to build deep and long-lasting collaborations with our partners to translate pioneering science into breakthroughs for patients.
We strongly believe that the key elements to a successful and lasting partnership are trust, shared values and openness. To revolutionize today’s standard of care, we are looking for best or first in class innovation in the following areas:
Roche is highly committed to making a contribution to areas of huge unmet need and societal burden through transformative science and expands its footprint in cardiovascular and metabolic diseases.
Partnering opportunities we are looking for:
Jean Eric Charoin
Search & Evaluation Lead Immunology, CVM & Infectious Diseases, Pharma Partnering
Contact Jean Eric CharoinWe are interested in collaborations on real world data, advanced analytics, digital tools and platform opportunities that:
Michael Scherer
Search & Evaluation Lead, Digital & Personalized Healthcare, Pharma Partnering
Contact Michael SchererWe are leading the way to advance science in inflammatory and autoimmune diseases. Partnering opportunities we are looking for:
Jean Eric Charoin
Search & Evaluation Lead Immunology, CVM & Infectious Diseases, Pharma Partnering
Contact Jean Eric CharoinWe are advancing innovation to combat infectious diseases like HBV, influenza and MDR. Partnering opportunities we are looking for:
Jean Eric Charoin
Search & Evaluation Lead Immunology, CVM & Infectious Diseases, Pharma Partnering
Contact Jean Eric CharoinWe focus on advances for neurodegenerative, psychiatric and neurodevelopmental disorders. Partnering opportunities we are looking for:
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering
Contact Hannah WilliamsWe focus on first- and best-in-class therapeutics in molecular targeted therapies and cancer immunotherapy. Partnering opportunities we are looking for:
Zineb El Fajoui
Search & Evaluation Lead Oncology, Pharma Partnering
Contact Zineb El FajouiWe are focusing on saving people’s eyesight from the leading causes of vision loss through pioneering therapies and cutting-edge research. Partnering opportunities we are looking for:
Hannah Williams
Search & Evaluation Lead Neuroscience, Ophthalmology & Rare Diseases, Pharma Partnering
Contact Hannah WilliamsWe focus on therapeutic modalities and enabling technologies. Partnering opportunities we are looking for:
Tomas Hejhal
Search & Evaluation Lead Research Technologies, Pharma Partnering
Contact Tomas HejhalResearch & Development is the essence and lifeblood of Roche - and we have a unique way to foster innovation together with our partners in Asia and across the world. Partnering opportunities we are looking for:
Mikio Kasahara
Director Business Development, Pharma Partnering Japan
Contact Mikio KasaharaWenjia Li
Associate Director Business Development, Pharma Partnering China, Taiwan & Singapore
Contact Wenjia LiHailey Jung
Business Development Project Leader, Pharma Partnering Korea
Contact Hailey JungLeveraging external innovation has always been central to our R&D strategy and, as such, supporting, encouraging and accessing early stage innovation is a critical aspect of our ability to discover and develop meaningful medicines for patients. Since some of the most cutting-edge science is happening in the UK, we are increasingly focusing on identifying and supporting great science in the UK. We are seeking partnering opportunities across all our therapeutic areas of interest, including digital and personalized healthcare and novel research technologies, in particular for the following:
During the collaboration conversations, a dedicated Alliance Director is assigned as the single point of contact to ensure successful continuation and an enduring relationship with our new partner.
Matthias Rueth
Global Head of Alliance & Asset Management, Pharma Partnering
Contact Matthias RuethOut-licensing and divestment decisions enable us to continue our investment in innovative R&D, supporting the development of novel medicines. In addition, it supports the further development of programs that could result in treatments for patients in disease areas and indications that are no longer of strategic focus for Roche and Genentech.